vaccine

Meanwhile in Oklahoma – 12.04.20

/ SupremeCmdr / Leave a comment

Meanwhile at the CDC…

We don’t have enough vaccine yet for all health care workers. We will eventually, but we don’t yet.

Helen Keipp Talbot — who is known by her middle name — raised serious concerns during the meeting of the Advisory Committee on Immunization Practices about using the vaccines in the frail elderly, noting there are no data yet to suggest the vaccines work in this population.

CDC advisory panel’s lone dissenter on why long-term care residents shouldn’t receive Covid-19 vaccine first — https://www.statnews.com/2020/12/03/cdc-advisory-panels-lone-dissenter-on-why-long-term-care-residents-shouldnt-receive-covid-19-vaccine-first/

Talbot is an associate professor of infectious diseases at Vanderbilt University. Despite the fact no one seems to be listening to her opinions, she makes some excellent observations.

Meanwhile back in Oklahoma

I’m confused as to why people are confused.

Oxford vaccine shows 90% efficacy in Phase-3 trial — Science Chronicle

/ SupremeCmdr / Leave a comment

Interim data analysis of Phase-3 trial of Oxford/AstraZeneca COVID-19 candidate vaccine (ChAdOx1 nCoV-2019) showed different efficacies in preventing COVID-19 disease. In the case of the regimen where a halved dose was used as a prime (first dose) followed by a standard dose of booster, the efficacy was 90%. However, when full doses (standard doses) were […]

Oxford vaccine shows 90% efficacy in Phase-3 trial — Science Chronicle

MMR Vaccine Study Shows Possible Protection Against Covid-19

/ SupremeCmdr / 1 Comment

More research is needed but if this study findings hold up we have a game changer.

“We found a statistically significant inverse correlation between mumps titer levels and COVID-19 severity in people under age 42 who have had MMR II vaccinations,” said lead study author Jeffrey E. Gold, president of World Organization, in Watkinsville, Georgia. “This adds to other associations demonstrating that the MMR vaccine may be protective against COVID-19. It also may explain why children have a much lower COVID-19 case rate than adults, as well as a much lower death rate. The majority of children get their first MMR vaccination around 12 to 15 months of age and a second one from 4 to 6 years of age.”

American Society for Microbiology. “MMR vaccine could protect against COVID-19, study shows.” ScienceDaily. http://www.sciencedaily.com/releases/2020/11/201120091157.htm (accessed November 22, 2020).

Oxford vaccine found safe and immunogenic in Phase 2 Trial Results— Science Chronicle

/ SupremeCmdr / 2 Comments

Results of the Phase-2 trial of the Oxford vaccine show that the vaccine is safe across age groups — younger (18-55 years age) and older adults (over 56 years age). In fact, older adults better tolerated the vaccine than younger adults, the results show. The vaccine also induced T cell immune responses and neutralising antibodies […]

Oxford vaccine found safe and immunogenic even in older adults — Science Chronicle

ATTENTION Anti-Vaxxers — (you probably don’t want this vaccine either)

/ SupremeCmdr / 1 Comment

The 30,000-person trial included 11,000 volunteers from communities of color, making up 37% of the total study population. It also included more than 7,000 volunteers over the age of 65 and more than 5,000 people under 65 who have high-risk medical conditions that put them at high risk of suffering from a severe infection, should they contract Covid, things like diabetes, severe obesity and heart disease. 

Moderna’s Covid-19 vaccine is strongly effective, early look at data show – https://www.statnews.com/2020/11/16/modernas-covid-19-vaccine-is-strongly-effective-early-look-at-data-show/?utm_campaign=rss

Refrigeration Requirements

The mRNA-1273 vaccine can be shipped and stored for up to 6 months at –20° C (about –4° F), a temperature maintained in most home or medical freezers, according to Moderna. The company expects that after the product thaws, it will remain stable at standard refrigerator temperatures of 2° to 8° C (36° to 46° F) for up to 30 days within the 6-month shelf life.

Because the mRNA-1273 vaccine is stable at these refrigerator temperatures, it can be stored at most physicians’ offices, pharmacies, and hospitals, the company notes. In contrast, the similar Pfizer BTN162b2 vaccine ― early results for which showed a 90% efficacy rate, as reported by Medscape Medical News ― requires shipment and storage at “deep freeze” conditions of –70° C or –80° C, which is more challenging from a logistic point of view.

Moderna’s mRNA-1273 can be kept at room temperature for up to 12 hours after removal from a refrigerator for patient administration. The vaccine will not require dilution prior to use.

Moderna: Interim Data Show 94.5% Efficacy for COVID-19 Vaccine, Will Seek FDA EUA — https://www.medscape.com/viewarticle/941023?src=rss

Game changer!

Pfizer and BioNTech Announce Vaccine Candidate Against COVID-19 Achieved Success in First Interim Analysis from Phase 3 Study

/ SupremeCmdr / Leave a comment

Vaccine candidate was found to be more than 90% effective in preventing COVID-19 in participants without evidence of prior SARS-CoV-2 infection in the first interim efficacy analysis

Analysis evaluated 94 confirmed cases of COVID-19 in trial participants

Study enrolled 43,538 participants, with 42% having diverse backgrounds, and no serious safety concerns have been observed; Safety and additional efficacy data continue to be collected

Submission for Emergency Use Authorization (EUA) to the U.S. Food and Drug Administration (FDA) planned for soon after the required safety milestone is achieved, which is currently expected to occur in the third week of November

Clinical trial to continue through to final analysis at 164 confirmed cases in order to collect further data and characterize the vaccine candidate’s performance against other study endpoints

Press Release — https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-vaccine-candidate-against

How Pfizer’s COVID-19 vaccine works: mRNA

“There was always a discussion: Is the spike protein the right target? Well, now we know it’s the right target,” Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, told STAT on Monday. “So, it’s not only immediate good news, it really is optimistic about what’s going to roll out in the next several months with the other vaccines.”

Four reasons for encouragement based on Pfizer’s Covid-19 vaccine results — https://www.statnews.com/2020/11/09/four-reasons-for-encouragement-based-on-pfizers-covid-19-vaccine-results/?utm_campaign=rss

Russia’s coronavirus vaccine elicits immune responses in Phase-1/2 trials — Science Chronicle

/ SupremeCmdr / 1 Comment

Russia’s Sputnik V vaccines for novel coronavirus have been found to be safe for a period of 42 days and capable of inducing antibody responses in all the 42 participants within 21 days. But the Phase-1/2 trials were open, not randomised, did not have a control group, and included totally 76 participants.

According to the authors, the unpublished data of animal studies show “robust humoral and cellular immune responses were elicited in non-human primates, providing protection from SARS-CoV-2 infection”. They also write that the vaccine showed “100% protectivity in a lethal model of SARS-CoV-2 challenge in immunosuppressed hamsters”. No antibody-dependent enhancement of infection was seen in vaccinated animals.

Russia’s coronavirus vaccine is safe, elicits immune responses in Phase-1/2 trials — Science Chronicle

Safe? 76 humans and an undisclosed number of hamsters.

Why am I not impressed?